Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Experimental RNAi02:15

Experimental RNAi

6.9K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
MicroRNAs01:22

MicroRNAs

3.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vitro Doxorubicin Delivery Using TPP-Folate-Dendrimer-Functionalized Gold Nanoclusters.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Functionalized Core/Shell Gold-Palladium Bimetallic Nanoparticles in Transferrin-Targeted Dual-Drug Delivery in a Cervical Cancer Cell Model.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Biocompatible Copolymerized Gold Nanoclusters: Anti-<i>TNF-α</i> siRNA Binding, Cellular Uptake, Cytotoxicity, Oxidative Stress and Cell Cycle Effects In Vitro.

Biomimetics (Basel, Switzerland)·2025
Same author

Isolation, Characterization, Antioxidant and Anticancer Activities of Compounds from <i>Erythrina caffra</i> Stem Bark Extract.

Antioxidants (Basel, Switzerland)·2025
Same author

Hydrogels as Suitable miRNA Delivery Systems: A Review.

Polymers·2025
Same author

Bio-Inspired Polymeric Solid Lipid Nanoparticles for siRNA Delivery: Cytotoxicity and Cellular Uptake In Vitro.

Polymers·2024

Related Experiment Video

Updated: Nov 25, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K

Anti-c-myc RNAi-Based Onconanotherapeutics.

Saffiya Habib1, Mario Ariatti1, Moganavelli Singh1

  • 1Nano-Gene and Drug Delivery Group, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag, Durban X54001, South Africa.

Biomedicines
|December 18, 2020
PubMed
Summary

Targeting the c-myc oncogene with RNA interference (RNAi) offers a promising cancer therapy. Nanoparticle carriers are crucial for delivering RNAi agents to silence c-myc effectively.

Keywords:
RNA interferencec-mycexpressiongene silencingnanosystemsoncogenesiRNA

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

8.2K

Related Experiment Videos

Last Updated: Nov 25, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

8.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Nanotechnology

Background:

  • The c-myc proto-oncogene is overexpressed in most human cancers, making it a key therapeutic target.
  • Inhibiting c-myc expression has demonstrated significant anti-cancer effects in early studies.
  • RNA interference (RNAi) offers a mechanism for targeted gene silencing, presenting a potential strategy for c-myc inhibition.

Purpose of the Study:

  • To review anti-c-myc RNAi-based nanosystems developed between 2005 and 2020.
  • To highlight the role of nanoparticle carriers in delivering RNAi effectors for c-myc gene silencing.
  • To assess the clinical viability of RNAi-based platforms for cancer treatment.

Main Methods:

  • Review of scientific literature focusing on RNAi-based anti-c-myc therapies.
  • Analysis of studies utilizing various nanoparticles (organic and inorganic) as carriers for small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids.
  • Evaluation of in vitro and in vivo assessments of these nanosystems.

Main Results:

  • Nanoparticles have been extensively investigated as carriers for anti-c-myc RNAi agents.
  • Diverse RNAi effectors, including siRNA, DsiRNA, and shRNA, have been employed.
  • Both organic and inorganic nanoparticles show potential for delivering these agents.

Conclusions:

  • RNAi-based nanosystems represent a promising avenue for developing novel anti-cancer therapeutics targeting c-myc.
  • The design and efficacy of nanoparticle carriers are critical for the clinical success of anti-c-myc RNAi strategies.
  • Continued research in this area holds potential for broadly applicable and effective cancer treatments.